![Neoleukin Therapeutics, Inc. logo](/logos/NLTX.webp)
Neoleukin Therapeutics, Inc.
NASDAQ:NLTX
Overview | Financials
Company Name | Neoleukin Therapeutics, Inc. |
Symbol | NLTX |
Currency | USD |
Price | 3.49 |
Market Cap | 8,199,685 |
Dividend Yield | 0% |
52-week-range | 3.42 - 18.8 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Ms. Donna M. Cochener-Metcalfe J.D. |
Website | https://www.neoleukin.com |
An error occurred while fetching data.
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD